IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2022 | $7.50 | Equal-Weight | Morgan Stanley |
SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
3 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
3 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will host a conference call and webcast to discuss the new SENTI-202 Phase 1 clinical data being presented at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 28, 2025 at 8:30 AM ET. The call will be hosted by Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder, and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer, of Senti Bio. Int
Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio KOL Connect segment now available here SOUTH SAN FRANCISCO, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the release of a Virtual Investor KOL segment featuring Stephen Strickland, MD, MSCI, leukemia researcher, Direc
SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that will participate in the Virtual Investor Closing Bell Series on Wednesday, April 23, 2025 at 4:00 PM ET. As part of the event, Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder, and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer, of Senti Bio will provide a corporate overview. In addition to the moderated discussion, there will be a live question and answer session. T
Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor
Company advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with lead candidate, SENTI-202, in clinical development for the treatment of acute myeloid leukemia (AML) Connect with the Company on Webull here SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform. Senti Bio's portal on the Webull CCS aims to provide an additional line of communicatio
SOUTH SAN FRANCISCO, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that three abstracts have been selected for an oral minisymposium and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL. Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio commented, "We are excited to present updated clinical and correlativ
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with gross proceeds of approximately $47.6 million from private investment in public equity (PIPE) financing – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2024 and provided a summary of rece
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio," or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the "Board"). "We are pleased to welcome Feng to our Board—he brings deep expertise in investment strategy and capital markets across multiple industries," said Timothy Lu, M.D., Ph.D., CEO of Senti Bio. "We look forward to the unique business perspectives he'll pro
– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced an expansion of its senior leadership team with the addition of Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations. Mr. Cross will join the Company on March 3, 2025. Mr. Siddiqui joined
– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – – Cash runway guidance extended into 2026 – SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has secured an additional investment of approximately $10.0 million in gross proceeds from Celadon Partners adding to the previously announced PIPE financing round. This additional funding brings the total
SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will host a conference call and webcast to discuss the new SENTI-202 Phase 1 clinical data being presented at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 28, 2025 at 8:30 AM ET. The call will be hosted by Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder, and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer, of Senti Bio. Int
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio," or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the "Board"). "We are pleased to welcome Feng to our Board—he brings deep expertise in investment strategy and capital markets across multiple industries," said Timothy Lu, M.D., Ph.D., CEO of Senti Bio. "We look forward to the unique business perspectives he'll pro
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma ("HCC") – SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration with Celest Therapeutics (Shanghai) Co. Ltd ("Celest"). SN301A utilizes the anti-GPC3 + crIL-15 (each as defined below) SENTI-301A Gene
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on November 26, 2024, the Compensation Committee of Senti Bio's Board of Directors granted to three new employees stock options to purchase an aggregate of 49,778 shares of the Company's common stock with a per share exercise price of $2.11. These awards were made under the Company's 2022 Inducement Equity Plan (the "Plan"). The above-described awards were each granted as an inducement material to the employees entering
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – – Dose escalation is continuing with additional response and durability data expected in 2025 – – Conference call scheduled on December 3 at 7:30am ET – SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-i
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Fran Schulz, a highly experienced biotechnology and financial executive, to the Senti Bio Board of Directors ("Board"). "We are excited to welcome Fran to the Senti Bio Board of Directors," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "Fran's deep expertise in the life sciences industry—spanning finance, strategic planning, operations, and transactions—wi
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2024 and provided a summary of recent pipeline and corporate highlights. "Over the past quarter, we have continued to execute on our clinical milestones and look forward to sharing initial results from the clinical trial of SENTI-202 before 2024 year-end," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "As we look toward 2025, we anticipate sharing add
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. Wainwright's 26th Annual Global Investment ConferenceFormat: Presentation and 1x1 MeetingsLocation: New York, NYPlease click here to access the pre-recorded presentation (available September 9, 2024, at 7:00 a.m. ET)Chardan's 8th Annual Genetic Medic
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2024 and provided a summary of recent corporate and pipeline highlights. "We have demonstrated important progress year to date, dosi
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant will support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer ("CAR-NK") investigational cell the
EFFECT - Senti Biosciences, Inc. (0001854270) (Filer)
EFFECT - Senti Biosciences, Inc. (0001854270) (Filer)
424B5 - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
S-3 - Senti Biosciences, Inc. (0001854270) (Filer)
S-3 - Senti Biosciences, Inc. (0001854270) (Filer)
10-K - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
SCHEDULE 13D - Senti Biosciences, Inc. (0001854270) (Subject)
SCHEDULE 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)
Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor